
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="7196EAE181CD818307EAE10036A02F7F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="tlcr">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Translational Lung Cancer Research">
<meta name="citation_title" content="Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis">
<meta name="citation_author" content="Sangtian Liu">
<meta name="citation_author_institution" content="Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author_institution" content="National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author" content="Wenhua Liang">
<meta name="citation_author_institution" content="Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author_institution" content="National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author" content="Shicui Quan">
<meta name="citation_author_institution" content="Departments of Pathology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;">
<meta name="citation_author" content="Qilin Deng">
<meta name="citation_author_institution" content="School of Medicine, Guangzhou Medical University, Guangzhou, China;">
<meta name="citation_author" content="Wenhai Fu">
<meta name="citation_author_institution" content="Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author_institution" content="National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author" content="Yalei Zhang">
<meta name="citation_author_institution" content="Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author_institution" content="National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author" content="Hong Du">
<meta name="citation_author_institution" content="Department of Pathology, Guangzhou First People’s Hospital, Guangzhou, China;">
<meta name="citation_author_institution" content="School of Medicine, South China University of Technology, Guangzhou, China">
<meta name="citation_author" content="Jianxing He">
<meta name="citation_author_institution" content="Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_author_institution" content="National Clinical Research Center for Respiratory Disease, Guangzhou, China;">
<meta name="citation_publication_date" content="2025 Mar 23">
<meta name="citation_volume" content="14">
<meta name="citation_issue" content="3">
<meta name="citation_firstpage" content="1032">
<meta name="citation_doi" content="10.21037/tlcr-24-711">
<meta name="citation_pmid" content="40248739">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/pdf/tlcr-14-03-1032.pdf">
<meta name="description" content="Lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations remains a significant clinical challenge, particularly when patients experience progression following EGFR-tyrosine kinase inhibitor (TKI) therapy. This case report ...">
<meta name="og:title" content="Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations remains a significant clinical challenge, particularly when patients experience progression following EGFR-tyrosine kinase inhibitor (TKI) therapy. This case report ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12000952">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.21037/tlcr-24-711"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/tlcr-14-03-1032.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12000952%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12000952/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12000952/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-tlcr.gif" alt="Translational Lung Cancer Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Translational Lung Cancer Research" title="Link to Translational Lung Cancer Research" shape="default" href="http://www.tlcr.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Transl Lung Cancer Res</button></div>. 2025 Mar 23;14(3):1032–1041. doi: <a href="https://doi.org/10.21037/tlcr-24-711" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.21037/tlcr-24-711</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Transl%20Lung%20Cancer%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Transl%20Lung%20Cancer%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Sangtian Liu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Sangtian Liu</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sangtian Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Wenhua Liang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Wenhua Liang</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenhua Liang</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Quan%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Shicui Quan</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Shicui Quan</span></h3>
<div class="p">
<sup>3</sup>Departments of Pathology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Quan%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shicui Quan</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deng%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Qilin Deng</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Qilin Deng</span></h3>
<div class="p">
<sup>4</sup>School of Medicine, Guangzhou Medical University, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deng%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qilin Deng</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Wenhai Fu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Wenhai Fu</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenhai Fu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Yalei Zhang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Yalei Zhang</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yalei Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Du%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Hong Du</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Hong Du</span></h3>
<div class="p">
<sup>5</sup>Department of Pathology, Guangzhou First People’s Hospital, Guangzhou, China;</div>
<div class="p">
<sup>6</sup>School of Medicine, South China University of Technology, Guangzhou, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Du%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hong Du</span></a>
</div>
</div>
<sup>5,</sup><sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Jianxing He</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Jianxing He</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jianxing He</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div id="aff2">
<sup>2</sup>National Clinical Research Center for Respiratory Disease, Guangzhou, China;</div>
<div id="aff3">
<sup>3</sup>Departments of Pathology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;</div>
<div id="aff4">
<sup>4</sup>School of Medicine, Guangzhou Medical University, Guangzhou, China;</div>
<div id="aff5">
<sup>5</sup>Department of Pathology, Guangzhou First People’s Hospital, Guangzhou, China;</div>
<div id="aff6">
<sup>6</sup>School of Medicine, South China University of Technology, Guangzhou, China</div>
<div class="author-notes p">
<div class="fn" id="afn1"><p><em>Contributions:</em> (I) Conception and design: S Liu; (II) Administrative support: J He, W Liang; (III) Provision of study materials or patients: Y Zhang, H Du; (IV) Collection and assembly of data: Q Deng; (V) Data analysis and interpretation: S Quan, W Fu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></div>
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline"><em>Correspondence to:</em> Jianxing He, MD, PhD. Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease &amp; National Clinical Research Center for Respiratory Disease, Datansha Campus, No. 28 Qiaozhong Middle Road, Liwan District, Guangzhou 510120, China; National Clinical Research Center for Respiratory Disease, Guangzhou, China. Email: <span>drjianxing.he@gmail.com</span>.</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Aug 13; Accepted 2024 Dec 19; Issue date 2025 Mar 31.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025 AME Publishing Company. All rights reserved.</div>
<p><em>Open Access Statement:</em> This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc-nd/4.0</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12000952  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40248739/" class="usa-link">40248739</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p>Lung adenocarcinoma harboring epidermal growth factor receptor (<em>EGFR</em>) mutations remains a significant clinical challenge, particularly when patients experience progression following <em>EGFR</em>-tyrosine kinase inhibitor (TKI) therapy. This case report explores the efficacy of pembrolizumab-based immunochemotherapy (ICT) in achieving a pathological complete response (pCR) and prolonged survival in a patient with <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC) after TKI failure.</p></section><section id="sec2"><h3 class="pmc_sec_title">Case Description</h3>
<p>A 74-year-old female patient with stage IVa <em>EGFR L858R</em>-mutated lung adenocarcinoma, progressing under multiple lines of <em>EGFR</em>-TKI therapy, was treated with pembrolizumab in combination with pemetrexed and carboplatin. Tumor response was assessed using radiological imaging and positron emission tomography-computed tomography (PET-CT). Pathological evaluation was conducted post-surgery, and the tumor microenvironment (TME) was analyzed using multiplex immunofluorescence (mIF) staining. Following four cycles of pembrolizumab-based ICT, the patient exhibited a significant reduction in tumor burden and mediastinal lymph node involvement, as confirmed by PET-CT. Surgical resection revealed a pCR with no viable tumor cells existed. The microenvironment analysis for tumor samples obtained post-progression on targeted therapy demonstrated that more than 50% of tumor cells expressing programmed cell death 1 ligand 1 (PD-L1), accompanying with higher infiltration of programmed death receptor 1 (PD-1)<sup>+</sup> CD8<sup>+</sup> T cells and PD-L1<sup>+</sup> CD68<sup>+</sup> macrophages in the tumor area compared to the stromal area. As for resected samples, substantial infiltration of CD45<sup>+</sup> immune cells, CD8<sup>+</sup> T lymphocytes, CD68<sup>+</sup> macrophages and immature tertiary lymphoid structures (TLSs) were detected.</p></section><section id="sec3"><h3 class="pmc_sec_title">Conclusions</h3>
<p>This case report highlights the potential of pembrolizumab-based ICT to induce a pCR and achieve long-term survival in <em>EGFR</em>-mutated NSCLC patients post-TKI failure. The favorable TME observed supports the rationale for this therapeutic approach and warrants further investigation in prospective clinical trials.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords: </strong> Epidermal growth factor receptor (<em>EGFR</em>), non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs), pathological complete response (pCR), case report</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="ba"><h2 class="obj_head">Highlight box.</h2>
<section id="sec4"><h3 class="pmc_sec_title">Key findings</h3>
<p>• A patient with stage IVa epidermal growth factor receptor (<em>EGFR</em>) <em>L858R</em>-mutated non-small cell lung cancer (NSCLC) achieved a pathological complete response (pCR) and prolonged survival after failing multiple lines of <em>EGFR</em>-tyrosine kinase inhibitor (TKI) therapy, following treatment with pembrolizumab-based immunochemotherapy (ICT). Tumor microenvironment analysis showed high programmed cell death 1 ligand 1 (PD-L1) expression on tumor cells and increased infiltration of immune cells, particularly PD-1<sup>+</sup> CD8<sup>+</sup> T cells and PD-L1<sup>+</sup> macrophages, in the tumor area compared to the stroma.</p></section><section id="sec5"><h3 class="pmc_sec_title">What is known and what is new?</h3>
<p>• <em>EGFR</em>-mutated NSCLC typically responds well to <em>EGFR</em>-TKIs, but resistance is common. Immune checkpoint inhibitors (ICIs) have shown promise in various cancers, though their role in <em>EGFR</em>-mutated NSCLC is less defined.</p>
<p>• This case report demonstrates that pembrolizumab-based ICT can achieve pCR and long-term survival in <em>EGFR</em>-mutated NSCLC post-TKI failure, suggesting a potential role for this approach in this patient population.</p></section><section id="sec6"><h3 class="pmc_sec_title">What is the implication, and what should change now?</h3>
<p>• The findings suggest that ICT may be a valuable treatment option for <em>EGFR</em>-mutated NSCLC patients who have progressed on TKIs. This could lead to reconsideration of treatment strategies, potentially integrating ICIs with chemotherapy earlier in the treatment sequence for these patients. Further prospective studies are needed to validate these findings and identify predictive biomarkers for response.</p></section></section><section id="sec7"><h2 class="pmc_sec_title">Introduction</h2>
<p>Lung adenocarcinoma with epidermal growth factor receptor (<em>EGFR</em>) mutations represents a distinct subset of non-small cell lung cancer (NSCLC) that typically responds well to <em>EGFR</em>-tyrosine kinase inhibitors (TKIs) (<a href="#r1" class="usa-link" aria-describedby="r1">1</a>-<a href="#r3" class="usa-link" aria-describedby="r3">3</a>). However, resistance to these targeted therapies is a common challenge, leading to disease progression and a poor prognosis for affected patients. The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for various malignancies (<a href="#r4" class="usa-link" aria-describedby="r4">4</a>,<a href="#r5" class="usa-link" aria-describedby="r5">5</a>), yet their role in <em>EGFR</em>-mutated NSCLC remains less defined due to the presumed molecularly driven nature of these tumors.</p>
<p>Recent studies have suggested that <em>EGFR</em>-mutated NSCLC may exhibit a more robust immune response than previously thought, potentially making them candidates for immunotherapy (<a href="#r6" class="usa-link" aria-describedby="r6">6</a>,<a href="#r7" class="usa-link" aria-describedby="r7">7</a>). The combination of ICIs with conventional chemotherapy has shown promise in enhancing antitumor activity by not only directly targeting tumor cells but also modulating the tumor immune microenvironment (TIME) to foster an immune-permissive milieu (<a href="#r8" class="usa-link" aria-describedby="r8">8</a>-<a href="#r10" class="usa-link" aria-describedby="r10">10</a>).</p>
<p>This case report describes a patient with <em>EGFR L858R</em>-mutated advanced NSCLC who experienced disease progression following multiple lines of <em>EGFR</em>-TKI therapy. The patient subsequently received pembrolizumab in combination with chemotherapy, achieving a pathological complete response (pCR) and prolonged survival. The investigation of the tumor microenvironment (TME) revealed a significant infiltration of immune cells and elevated expression of programmed cell death 1 ligand 1 (PD-L1), supporting the rationale for this therapeutic approach. This case underscores the potential of immunochemotherapy (ICT) in <em>EGFR</em>-mutated NSCLC and contributes to the growing body of evidence suggesting that these patients may benefit from immunotherapeutic strategies, particularly when integrated with conventional cytotoxic agents. We present this case in accordance with the CARE reporting checklist (available at <a href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/rc" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/rc</a>).</p></section><section id="sec8"><h2 class="pmc_sec_title">Case presentation</h2>
<section id="sec9"><h3 class="pmc_sec_title">Patient information</h3>
<p>In September 2019, a 74-year-old female patient with no history of smoking presented with symptoms of shortness of breath, cough, and hemoptysis. Bronchoscopic lung biopsy was performed for her and she was diagnosed with stage IVa (cT4N2M1a) lung adenocarcinoma located in the right upper lobe, accompanied by multiple metastases in the ipsilateral lung, as well as involvement of the pleura and mediastinal lymph nodes. Subsequent next-generation sequencing (NGS) identified an <em>EGFR p.L858R</em> mutation in exon 21 and a <em>TP53 p.R248L</em> mutation in exon 7.</p>
<p>Commencing on October 11, 2019, the patient was administered icotinib, a first-generation <em>EGFR</em>-TKI (125 mg orally, three times daily) in conjunction with pemetrexed [500 mg/m<sup>2</sup> intravenously (IV), on day 1 of a 21-day cycle] and nedaplatin (80 mg/m<sup>2</sup> IV, on day 1 of a 21-day cycle) as first-line therapy. This regimen resulted in a radiologic partial response (PR) after 2 months. Nevertheless, following six cycles of treatment, disease progression was observed. At this juncture, adequate pleural effusion was obtained for repeat NGS, which did not reveal any new genetic mutations. Beginning on April 28, 2020, the patient commenced second-line treatment with amonertinib, third-generation <em>EGFR</em>-TKI (110 mg orally, once daily) in combination with anlotinib, a TKI that can effectively inhibit multiple kinases such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) (12 mg orally, once daily for 2 weeks, followed by a 1-week drug-free period, with each cycle lasting 3 weeks) for a duration of 3 months. Computed tomography (CT) scans indicated stable disease (SD) at the sixth week; however, disease progression was observed after 3 months. Consequently, the patient underwent a comprehensive examination, which included whole-body positron emission tomography (PET)-CT, cranial magnetic resonance imaging (MRI), and tumor re-biopsy. The disease persisted at stage IVa (cT4N2M1a) without evidence of extra-thoracic metastases, and the <em>EGFR T790M</em> mutation was identified via NGS. Consequently, a treatment regimen comprising osimertinib (80 mg orally, once daily) in combination with bevacizumab (350 mg IV, on day 1 of a 21-day cycle) was initiated on August 3, 2020. Regrettably, disease progression was observed 2 months later (<a href="#f1" class="usa-link"><em>Figures 1,2A</em></a>).</p>
<figure class="fig xbox font-sm" id="f1"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12000952_tlcr-14-03-1032-f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2a6/12000952/0f24a74170d5/tlcr-14-03-1032-f1.jpg" loading="lazy" height="187" width="792" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/f1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Treatment timeline. ICT, immunochemotherapy; m, months; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; pCR, pathological complete response; PD, progressed disease; PET-CT, positron emission tomography-computed tomography; PFS, progression-free survival; PR, partial response; SD, stable disease.</p></figcaption></figure><figure class="fig xbox font-sm" id="f2"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12000952_tlcr-14-03-1032-f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2a6/12000952/240f12d4bdc1/tlcr-14-03-1032-f2.jpg" loading="lazy" height="644" width="791" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/f2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Change of targeted tumor lesions upon treatment. (A) The change of tumor lesions by <em>EGFR</em>-TKI. (B) The change of tumor lesions by ICT. (C) Tumor lesions by PET-CT before and after ICT. Red arrows denoted major target lesions; green arrows denoted secondary target lesions; and yellow arrows denoted mediastinal lymph nodes. <em>EGFR</em>-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; ICT, immunochemotherapy; PET-CT, positron emission tomography-computed tomography.</p></figcaption></figure><p>Recent studies have confirmed the efficacy of chemotherapy combined with ICIs with or without anti-VEGF antibodies among those with resistance to <em>EGFR</em>-TKIs (<a href="#r8" class="usa-link" aria-describedby="r8">8</a>,<a href="#r9" class="usa-link" aria-describedby="r9">9</a>,<a href="#r11" class="usa-link" aria-describedby="r11">11</a>). As the CT scans showed a cavitary lesion, additional anti-VEGF antibody would make it prone to pulmonary hemorrhage(<a href="#r12" class="usa-link" aria-describedby="r12">12</a>). So, an ICI based ICT was considered for this patient, consisting of pembrolizumab (200 mg IV on day 1 of a 3-week cycle) with pemetrexed (500 mg/m<sup>2</sup> IV on day 1 of a 3-week cycle) and carboplatin (dosage calculated as area under the curve (AUC) (5 mg/mL·min) × (creatinine clearance + 25), administered IV on day 1 of a 3-week cycle) since October 10, 2020. Following two cycles of this treatment regimen, a chest CT scan indicated a PR, with a significant reduction in multiple tumor lesions and mediastinal lymph nodes. Upon completion of four cycles of ICT, the patient underwent a PET-CT scan for further evaluation. Compared to the initial assessment conducted in August 2020, there was a significant reduction in multiple tumor lesions, the disappearance of certain cavities, and a marked attenuation in glucose metabolism (<a href="#f1" class="usa-link"><em>Figures 1,2B,2C</em></a>).</p>
<p>At this juncture, a multidisciplinary consultation was convened for the patient. Following a comprehensive evaluation of the medical team’s recommendations and the patient’s preferences, a “naked eye 3D thoracoscopic right upper lobectomy resection” was performed on March 3, 2021. Histopathological examination of the resected specimen revealed extensive inflammation and fibrosis, comprising 95% of the tissue, and necrosis, accounting for 5%, with no viable cancer cells detected. Furthermore, there was an absence of intravascular tumor emboli, nerve bundle involvement, pleural invasion, and lymph node metastases (0/5). According to the Mandard tumor regression grading system (<a href="#r13" class="usa-link" aria-describedby="r13">13</a>), it was classified as grade 1, indicating a pCR. The patient experienced an uneventful recovery and was discharged without any complications related to the surgical procedure. Postoperatively, she underwent regular adjuvant therapy with pembrolizumab and pemetrexed every 3 to 4 weeks. Follow-up chest CT scans were performed every 3 months. The patient has maintained a favorable physical condition, exhibiting progression-free survival (PFS) for over 40 months, with no indications of disease advancement observed (<a href="#f1" class="usa-link"><em>Figure 1</em></a>).</p></section><section id="sec10"><h3 class="pmc_sec_title">TME exploration</h3>
<p>As it reported, <em>EGFR</em> mutations in NSCLC promote the development of a non-inflammatory TIME, resulting in limited infiltration of immune cells in tumor tissues (<a href="#r14" class="usa-link" aria-describedby="r14">14</a>,<a href="#r15" class="usa-link" aria-describedby="r15">15</a>). <em>EGFR</em>-TKIs can change the quantity of immune cells, initially increasing the levels of CD8<sup>+</sup> T cells and dendritic cells in TME while inhibiting Foxp3 regulatory T cells (Tregs) and M2-like polarization (<a href="#r7" class="usa-link" aria-describedby="r7">7</a>,<a href="#r16" class="usa-link" aria-describedby="r16">16</a>). To investigate the characteristics of the TIME, we performed multiplex immunofluorescence (mIF) staining using 4',6-diamidino-2-phenylindole (DAPI), pan-cytokeratin (pan-CK), CD45, CD8, CD68, programmed death receptor 1 (PD-1), and PD-L1 on biopsied tumor samples obtained post-progression on targeted therapy, as well as on samples from surgical resections (<a href="#f3" class="usa-link"><em>Figure 3</em></a>). For the biopsied tumor tissues, five distinct tumor and stromal regions were randomly selected for subsequent statistical analysis. As illustrated in <a href="#f3" class="usa-link"><em>Figures 3A-3C,4A,4B</em></a>, the tumor regions predominantly consisted of pan-CK<sup>+</sup> tumor cells, with minimal infiltration by immune cells. In the stromal regions, CD45<sup>+</sup> immune cells constituted 30–40% of all nucleated cells, exhibiting a significantly higher density compared to the tumor regions. The distribution of CD68<sup>+</sup> macrophages was approximately similar to that of CD45<sup>+</sup> immune cells. However, there was no significant difference in the distribution of CD8<sup>+</sup> T cells between the tumor and stromal regions (<a href="#f4" class="usa-link"><em>Figure 4B</em></a>). Notably, more than half of the tumor cells expressed PD-L1 across all tumor regions (<a href="#f4" class="usa-link"><em>Figure 4C</em></a>). The proportion of PD-1 positive CD8<sup>+</sup> T cells and PD-L1 positive CD68<sup>+</sup> macrophages was significantly higher in the tumor area compared to the stromal area (<a href="#f4" class="usa-link"><em>Figure 4D</em></a>). In the resected sample, there was a substantial infiltration of CD45<sup>+</sup> immune cells, CD8<sup>+</sup> T lymphocytes, CD68<sup>+</sup> macrophages, and immature tertiary lymphoid structures (TLSs), with no viable tumor cells detected (<a href="#f3" class="usa-link"><em>Figure 3D,3E</em></a>).</p>
<figure class="fig xbox font-sm" id="f3"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12000952_tlcr-14-03-1032-f3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2a6/12000952/a4782e0b9cd1/tlcr-14-03-1032-f3.jpg" loading="lazy" height="577" width="694" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/f3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>HE staining and mIF staining. (A) HE and mIF illustration of re-biopsy tumor tissue, panorama and high-magnification image of tumor region and stroma region. (B,C) Specific immunofluorescence channel of tumor region and stroma region. (D,E) HE and mIF illustration of resected tumor sample. The markers of mIF are DAPI (blue), pan-CK (white), PD-L1 (green), CD45 (red), CD68 (yellow), CD8 (bright blue), and PD-1 (orange). CK, cytokeratin; DAPI, 4',6-diamidino-2-phenylindole; HE, hematoxylin and eosin; mIF, multiplex immunofluorescence; PD-1, programmed death receptor 1; PD-L1, expressing programmed cell death 1 ligand 1.</p></figcaption></figure><figure class="fig xbox font-sm" id="f4"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12000952_tlcr-14-03-1032-f4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2a6/12000952/4800a5875338/tlcr-14-03-1032-f4.jpg" loading="lazy" height="613" width="770" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/f4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Statistical analysis based on five randomly selected tumor regions and stroma regions. (A) The cell components in tumor region and stroma region. (B) The density of CD45<sup>+</sup> immune cells, CD8<sup>+</sup> T cell and CD68<sup>+</sup> macrophage in tumor region and stroma region. (C) The expression of PD-L1 on tumor cells. (D) The proportion of PD-1<sup>+</sup> CD8<sup>+</sup> T cells and PD-L1<sup>+</sup> CD68<sup>+</sup> macrophages in tumor region and stroma region. PD-1, programmed death receptor 1; PD-L1, expressing programmed cell death 1 ligand 1.</p></figcaption></figure><p>All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.</p></section></section><section id="sec11"><h2 class="pmc_sec_title">Discussion</h2>
<p>Currently, the use of <em>EGFR</em>-TKI as neoadjuvant therapy has demonstrated limited pathological regression, with the major pathological response (MPR; defined as viable tumor cells constituting less than 10%) ranging from 9% to 22%, and only a few instances of pCR have been observed (<a href="#r10" class="usa-link" aria-describedby="r10">10</a>,<a href="#r17" class="usa-link" aria-describedby="r17">17</a>-<a href="#r21" class="usa-link" aria-describedby="r21">21</a>). The case presented here is a remarkable example of a patient with advanced NSCLC and <em>EGFR</em>
<em>L858R</em> mutation achieving a pCR following treatment with pembrolizumab combined with chemotherapy, despite progressive disease under multiple lines of targeted therapy. This case underscores the potential of ICIs in reshaping the treatment paradigm for <em>EGFR</em>-mutated lung cancer, particularly when integrated with conventional chemotherapy.</p>
<p>It was previously believed that NSCLC patients with <em>EGFR</em> sensitive mutations should avoid ICI treatment, and they were typically excluded from large, multicenter, phase III clinical trials involving ICI-based immunotherapy (<a href="#r22" class="usa-link" aria-describedby="r22">22</a>). The use of pembrolizumab in <em>EGFR</em>-mutated lung cancer has been a subject of debate due to the predominantly molecularly driven nature of these tumors (<a href="#r23" class="usa-link" aria-describedby="r23">23</a>-<a href="#r25" class="usa-link" aria-describedby="r25">25</a>). However, recent studies have indicated that ICT could serve as a palliative treatment option for patients experiencing progression on <em>EGFR</em>-TKIs (<a href="#r26" class="usa-link" aria-describedby="r26">26</a>). The Impower 150 trial was the first to suggest that patients with <em>EGFR</em>-sensitive NSCLC might benefit from a combination of atezolizumab, bevacizumab, and chemotherapy. A Phase II trial investigating the combination of toripalimab (an anti-PD-1 antibody) with chemotherapy reported a median PFS of 7.0 months and an overall survival of 23.5 months as second-line treatment for <em>EGFR</em>-mutated NSCLC, supporting its application in those population (<a href="#r8" class="usa-link" aria-describedby="r8">8</a>). Similarly, the ORIENT-31 study demonstrated that the combination of sintilimab, IBI305, and chemotherapy resulted in a median PFS of 6.9 months with good tolerability (<a href="#r9" class="usa-link" aria-describedby="r9">9</a>). In recent KEYNOTE-789 (<a href="#r27" class="usa-link" aria-describedby="r27">27</a>) and CheckMate-722 (<a href="#r28" class="usa-link" aria-describedby="r28">28</a>) trials, the results shown no superiority of chemotherapy combined with pembrolizumab or nivolumab over chemotherapy alone in <em>EGFR</em>-mutated NSCLC patients who have progressed on <em>EGFR</em>-TKIs. Although the required number of PFS events in CheckMate-722 was not reached, the study found that patients receiving nivolumab with chemotherapy had an improved OS (19.4 <em>vs.</em> 15.9 months) than chemo-alone. Those differences in outcomes may be attributed to the heterogeneity of <em>EGFR</em>-mutated NSCLC, the strategy of <em>EGFR</em>-TKI selection, and the distinct immune microenvironment.</p>
<p>In our case, combining economic considerations and therapeutic efficacy, the patient was administered with icotinib in conjunction with pemetrexed and nedaplatin as the first-line treatment and achieved a PR initially. However, disease progression was observed after 6 months. The third generation <em>EGFR</em>-TKI seems not sensitive for her despite positive <em>T790M</em> mutation. Therefore, a combination of ICI with chemotherapy was recommended. Unexpectedly, the patient responded well. In contrast to prior studies, this female patient underwent surgical intervention after four cycles of ICT, enabling an assessment of pathological tumor regression and the TME. Pathological analysis indicated that the resected tumor bed was predominantly composed of immune cells and fibroblasts, with an absence of viable tumor cells. To explore potential factors associated with the efficacy of immunotherapy, mIF analysis of re-biopsied tumor tissue was performed to investigate the characteristics of TME. The results demonstrated a high PD-L1 expression on tumor cells and abundant immune cell infiltration in stroma region, which may be due to various previous treatments altered tumor heterogeneity, leading to increased immune cell infiltration and PD-L1 expression in TME (<a href="#r29" class="usa-link" aria-describedby="r29">29</a>). As previous studies revealed (<a href="#r30" class="usa-link" aria-describedby="r30">30</a>), <em>EGFR</em>-TKIs could increase the infiltration of CD8<sup>+</sup> T cells and dendritic cells in TIME while inhibiting Foxp3 Tregs and M2-like polarization (<a href="#r7" class="usa-link" aria-describedby="r7">7</a>). As for PD-L1 expression, the outcomes after TKI treatment remain controversial (<a href="#r15" class="usa-link" aria-describedby="r15">15</a>). <em>EGFR</em> pathway can alter tumor PD-L1 expression levels through various intracellular and extracellular mechanisms. Sensitive <em>EGFR</em>-TKIs treatment could downregulate tumor PD-L1 expression, while the PD-L1 expression level in <em>EGFR</em>-TKI-resistant tumors may increase. Amplification of mesenchymal-epidermal transition (MET), hepatocyte growth factor (HGF), and <em>EGFR T790M</em> could also upregulate tumor PD-L1 expression through signaling pathways such as PI3K/Akt, MAPK, and NF-κB (<a href="#r31" class="usa-link" aria-describedby="r31">31</a>).</p>
<p>Notably, there was a higher proportion of PD-1<sup>+</sup> CD8<sup>+</sup> lymphocytes and PD-L1<sup>+</sup> macrophages within the tumor regions compared to the stromal areas. CD8<sup>+</sup> lymphocytes can directly kill cells and are generally considered key participants in tumor-specific immune responses. High expression of PD-1 induces apoptosis in CD8<sup>+</sup> lymphocytes. An increase in the number of PD-1<sup>+</sup> CD8<sup>+</sup> lymphocytes often indicates that the immune response within the TME is in a suppressed state, inhibiting the anti-tumor effects of lymphocytes and making it difficult to effectively eliminate tumor cells (<a href="#r15" class="usa-link" aria-describedby="r15">15</a>). PD-L1 is an inhibitory molecule expressed on the surface of tumor cells and certain immune cells, which can inhibit cellular activity by binding to the PD-1 receptor. Similarly, the increase in PD-L1<sup>+</sup> macrophages also reflect the immune evasion mechanisms within TME (<a href="#r15" class="usa-link" aria-describedby="r15">15</a>). These findings suggest a functionally impaired immune infiltration, which may contribute to the ineffectiveness of <em>EGFR</em>-TKI therapy (<a href="#r32" class="usa-link" aria-describedby="r32">32</a>). The subsequent application of ICT following <em>EGFR</em>-TKI treatment appeared to successfully restore impaired immune function and enhance immune infiltration, as the CD45<sup>+</sup> immune cells, CD8<sup>+</sup> T lymphocytes, CD68<sup>+</sup> macrophages, and TLSs were substantially infiltrated in the resected samples. These findings support the notion that, despite <em>EGFR</em> mutations, certain lung cancers can respond dramatically to immunotherapy, especially when combined with chemotherapy to enhance the immune response.</p>
<p>The spatial distribution of immune cells is another important indicator. Some studies have shown that the extracellular matrix (ECM) can both promote the migration of immune cells and enhance their tumor-killing effects, as well as inhibit the activation of immune cells, which may indicate the tumor’s impact on and destructive capability against surrounding tissues (<a href="#r33" class="usa-link" aria-describedby="r33">33</a>). At the same time, the tumor-to-stroma ratio of immune cells can be used to reflect the status of the TME and assess treatment responses and prognosis. The relationship between immune cells and stroma can reflect the immune status of the TME and serves as an important metric for evaluating tumor immune evasion, immune suppression, and immune activation. During the treatment process, the tumor environment can recruit suppressive immune cells such as Tregs and tumor-associated macrophages (TAMs) through various pathways, leading to the occurrence of resistance events (<a href="#r34" class="usa-link" aria-describedby="r34">34</a>). The ratio of immune cells to tumor-stroma not only reveals the biological characteristics of the tumor, but also helps guide clinical decisions and personalized treatment strategies. What unfortunate was that we were unable to obtain tumor samples prior to TKI treatment for TME assessment, and thus unable to conduct dynamic comparative analysis of the TME before and after targeted therapy.</p>
<p>This case provides valuable insights for future treatment strategies in <em>EGFR</em>-mutated lung cancer. The success of pembrolizumab in combination with chemotherapy suggests that this approach should be considered in patients with progressive disease under targeted therapy, particularly those with evidence of an active immune response as indicated by TME analysis. TME has significant clinical implications in guiding anti-tumor therapies, and exploring how <em>EGFR</em> mutations alter TME, as well as the effects of targeted therapies on the immune microenvironment, may help optimize treatment strategies and provide new therapeutic approaches for <em>EGFR</em>-TKI resistance. Additionally, the identification of predictive biomarkers that can stratify patients likely to benefit from this combination is crucial for optimizing treatment outcomes.</p>
<p>While this case is encouraging, it is based on a single patient and should be interpreted with caution. Larger prospective studies are needed to validate these findings and to identify the specific characteristics of patients who are most likely to benefit from this treatment approach. Additionally, further research is required to understand the long-term outcomes, including the durability of response and potential for recurrence, in patients achieving a pCR with this regimen.</p></section><section id="sec12"><h2 class="pmc_sec_title">Conclusions</h2>
<p>In conclusion, this case report highlights the potential of combining pembrolizumab with chemotherapy in achieving a pCR in a patient with <em>EGFR</em>-mutated lung adenocarcinoma who had progressed on multiple lines of targeted therapy. The exploration of the TME further elucidates the complex interplay between the immune system and tumor cells, providing a rationale for the observed response. Future studies should aim to corroborate these findings and refine the selection criteria for patients most likely to benefit from this innovative treatment approach.</p></section><section id="sec13"><h2 class="pmc_sec_title">Supplementary</h2>
<section class="sm xbox font-sm" id="supplementary-material1"><div class="caption p"><p>The article’s supplementary files as</p></div></section><section class="sm xbox font-sm" id="su1"><div class="media p" id="d67e727">
<div class="caption">
<a href="/articles/instance/12000952/bin/tlcr-14-03-1032-rc.pdf" data-ga-action="click_feat_suppl" class="usa-link">tlcr-14-03-1032-rc.pdf</a><sup> (156.9KB, pdf) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.21037/tlcr-24-711</div>
</div>
<div class="media p" id="d67e730">
<div class="caption">
<a href="/articles/instance/12000952/bin/tlcr-14-03-1032-coif.pdf" data-ga-action="click_feat_suppl" class="usa-link">tlcr-14-03-1032-coif.pdf</a><sup> (650.9KB, pdf) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.21037/tlcr-24-711</div>
</div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>None.</p></section><section id="notes1"><p><em>Ethical Statement:</em> The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1"><p><em>Reporting Checklist:</em> The authors have completed the CARE reporting checklist. Available at <a href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/rc" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/rc</a></p></div>
<div class="fn p" id="fn3"><p><em>Funding:</em> This study was supported by grants from the National Nature Science Foundation of China (No. 82203004) and the China Postdoctoral Science Foundation (No. 2022M710896).</p></div>
<div class="fn p" id="fn4"><p><em>Conflicts of Interest:</em> All authors have completed the ICMJE uniform disclosure form (available at <a href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/coif" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/coif</a>). W.L. serves as an unpaid Associate Editor-in-Chief of <em>Translational Lung Cancer Research</em> from May 2024 to April 2025. All authors report grants from the National Nature Science Foundation of China (No. 82203004) and the China Postdoctoral Science Foundation (No.2022M710896). The authors have no other conflicts of interest to declare.</p></div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="r1">
<span class="label">1.</span><cite>Mok TS, Wu YL, Thongprasert S, et al. 
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med
2009;361:947-57. 10.1056/NEJMoa0810699
</cite> [<a href="https://doi.org/10.1056/NEJMoa0810699" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19692680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Gefitinib%20or%20carboplatin-paclitaxel%20in%20pulmonary%20adenocarcinoma.&amp;author=TS%20Mok&amp;author=YL%20Wu&amp;author=S%20Thongprasert&amp;volume=361&amp;publication_year=2009&amp;pages=947-57&amp;pmid=19692680&amp;doi=10.1056/NEJMoa0810699&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r2">
<span class="label">2.</span><cite>Soria JC, Ohe Y, Vansteenkiste J, et al. 
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
2018;378:113-25. 10.1056/NEJMoa1713137
</cite> [<a href="https://doi.org/10.1056/NEJMoa1713137" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29151359/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Osimertinib%20in%20Untreated%20EGFR-Mutated%20Advanced%20Non-Small-Cell%20Lung%20Cancer.&amp;author=JC%20Soria&amp;author=Y%20Ohe&amp;author=J%20Vansteenkiste&amp;volume=378&amp;publication_year=2018&amp;pages=113-25&amp;pmid=29151359&amp;doi=10.1056/NEJMoa1713137&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r3">
<span class="label">3.</span><cite>Zhou C, Wu YL, Chen G, et al. 
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
2011;12:735-42. 10.1016/S1470-2045(11)70184-X
</cite> [<a href="https://doi.org/10.1016/S1470-2045(11)70184-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21783417/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Erlotinib%20versus%20chemotherapy%20as%20first-line%20treatment%20for%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20(OPTIMAL,%20CTONG-0802):%20a%20multicentre,%20open-label,%20randomised,%20phase%203%20study.&amp;author=C%20Zhou&amp;author=YL%20Wu&amp;author=G%20Chen&amp;volume=12&amp;publication_year=2011&amp;pages=735-42&amp;pmid=21783417&amp;doi=10.1016/S1470-2045(11)70184-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r4">
<span class="label">4.</span><cite>Mok TSK, Wu YL, Kudaba I, et al. 
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
2019;393:1819-30. 10.1016/S0140-6736(18)32409-7
</cite> [<a href="https://doi.org/10.1016/S0140-6736(18)32409-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30955977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Pembrolizumab%20versus%20chemotherapy%20for%20previously%20untreated,%20PD-L1-expressing,%20locally%20advanced%20or%20metastatic%20non-small-cell%20lung%20cancer%20(KEYNOTE-042):%20a%20randomised,%20open-label,%20controlled,%20phase%203%20trial.&amp;author=TSK%20Mok&amp;author=YL%20Wu&amp;author=I%20Kudaba&amp;volume=393&amp;publication_year=2019&amp;pages=1819-30&amp;pmid=30955977&amp;doi=10.1016/S0140-6736(18)32409-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r5">
<span class="label">5.</span><cite>Paz-Ares L, Luft A, Vicente D, et al. 
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
2018;379:2040-51. 10.1056/NEJMoa1810865
</cite> [<a href="https://doi.org/10.1056/NEJMoa1810865" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30280635/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Pembrolizumab%20plus%20Chemotherapy%20for%20Squamous%20Non-Small-Cell%20Lung%20Cancer.&amp;author=L%20Paz-Ares&amp;author=A%20Luft&amp;author=D%20Vicente&amp;volume=379&amp;publication_year=2018&amp;pages=2040-51&amp;pmid=30280635&amp;doi=10.1056/NEJMoa1810865&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r6">
<span class="label">6.</span><cite>Isomoto K, Haratani K, Hayashi H, et al. 
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Clin Cancer Res
2020;26:2037-46. 10.1158/1078-0432.CCR-19-2027
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-2027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31937613/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Impact%20of%20EGFR-TKI%20Treatment%20on%20the%20Tumor%20Immune%20Microenvironment%20in%20EGFR%20Mutation-Positive%20Non-Small%20Cell%20Lung%20Cancer.&amp;author=K%20Isomoto&amp;author=K%20Haratani&amp;author=H%20Hayashi&amp;volume=26&amp;publication_year=2020&amp;pages=2037-46&amp;pmid=31937613&amp;doi=10.1158/1078-0432.CCR-19-2027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r7">
<span class="label">7.</span><cite>Jia Y, Li X, Jiang T, et al. 
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
Int J Cancer
2019;145:1432-44. 10.1002/ijc.32191
</cite> [<a href="https://doi.org/10.1002/ijc.32191" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30784054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&amp;title=EGFR-targeted%20therapy%20alters%20the%20tumor%20microenvironment%20in%20EGFR-driven%20lung%20tumors:%20Implications%20for%20combination%20therapies.&amp;author=Y%20Jia&amp;author=X%20Li&amp;author=T%20Jiang&amp;volume=145&amp;publication_year=2019&amp;pages=1432-44&amp;pmid=30784054&amp;doi=10.1002/ijc.32191&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r8">
<span class="label">8.</span><cite>Jiang T, Wang P, Zhang J, et al. 
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
Signal Transduct Target Ther
2021;6:355. 10.1038/s41392-021-00751-9
</cite> [<a href="https://doi.org/10.1038/s41392-021-00751-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8517012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34650034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Signal%20Transduct%20Target%20Ther&amp;title=Toripalimab%20plus%20chemotherapy%20as%20second-line%20treatment%20in%20previously%20EGFR-TKI%20treated%20patients%20with%20EGFR-mutant-advanced%20NSCLC:%20a%20multicenter%20phase-II%20trial.&amp;author=T%20Jiang&amp;author=P%20Wang&amp;author=J%20Zhang&amp;volume=6&amp;publication_year=2021&amp;pages=355&amp;pmid=34650034&amp;doi=10.1038/s41392-021-00751-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r9">
<span class="label">9.</span><cite>Lu S, Wu L, Jian H, et al. 
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
2022;23:1167-79. 10.1016/S1470-2045(22)00382-5
</cite> [<a href="https://doi.org/10.1016/S1470-2045(22)00382-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35908558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Sintilimab%20plus%20bevacizumab%20biosimilar%20IBI305%20and%20chemotherapy%20for%20patients%20with%20EGFR-mutated%20non-squamous%20non-small-cell%20lung%20cancer%20who%20progressed%20on%20EGFR%20tyrosine-kinase%20inhibitor%20therapy%20(ORIENT-31):%20first%20interim%20results%20from%20a%20randomised,%20double-blind,%20multicentre,%20phase%203%20trial.&amp;author=S%20Lu&amp;author=L%20Wu&amp;author=H%20Jian&amp;volume=23&amp;publication_year=2022&amp;pages=1167-79&amp;pmid=35908558&amp;doi=10.1016/S1470-2045(22)00382-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r10">
<span class="label">10.</span><cite>Bian D, Sun L, Hu J, et al. 
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.
Nat Commun
2023;14:4655. 10.1038/s41467-023-40349-z
</cite> [<a href="https://doi.org/10.1038/s41467-023-40349-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10400609/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37537219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Neoadjuvant%20Afatinib%20for%20stage%20III%20EGFR-mutant%20non-small%20cell%20lung%20cancer:%20a%20phase%20II%20study.&amp;author=D%20Bian&amp;author=L%20Sun&amp;author=J%20Hu&amp;volume=14&amp;publication_year=2023&amp;pages=4655&amp;pmid=37537219&amp;doi=10.1038/s41467-023-40349-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r11">
<span class="label">11.</span><cite>Socinski MA, Jotte RM, Cappuzzo F, et al. 
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med
2018;378:2288-301. 10.1056/NEJMoa1716948
</cite> [<a href="https://doi.org/10.1056/NEJMoa1716948" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29863955/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Atezolizumab%20for%20First-Line%20Treatment%20of%20Metastatic%20Nonsquamous%20NSCLC.&amp;author=MA%20Socinski&amp;author=RM%20Jotte&amp;author=F%20Cappuzzo&amp;volume=378&amp;publication_year=2018&amp;pages=2288-301&amp;pmid=29863955&amp;doi=10.1056/NEJMoa1716948&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r12">
<span class="label">12.</span><cite>Zhao Y, Guo S, Deng J, et al. 
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Int J Biol Sci
2022;18:3845-58. 10.7150/ijbs.70958
</cite> [<a href="https://doi.org/10.7150/ijbs.70958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9254480/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35813484/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Biol%20Sci&amp;title=VEGF/VEGFR-Targeted%20Therapy%20and%20Immunotherapy%20in%20Non-small%20Cell%20Lung%20Cancer:%20Targeting%20the%20Tumor%20Microenvironment.&amp;author=Y%20Zhao&amp;author=S%20Guo&amp;author=J%20Deng&amp;volume=18&amp;publication_year=2022&amp;pages=3845-58&amp;pmid=35813484&amp;doi=10.7150/ijbs.70958&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r13">
<span class="label">13.</span><cite>Mandard AM, Dalibard F, Mandard JC, et al. 
Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
Cancer
1994;73:2680-6. 
</cite> [<a href="https://doi.org/10.1002/1097-0142(19940601)73:11&amp;#x0003c;2680::aid-cncr2820731105&amp;#x0003e;3.0.co;2-c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8194005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Pathologic%20assessment%20of%20tumor%20regression%20after%20preoperative%20chemoradiotherapy%20of%20esophageal%20carcinoma.%20Clinicopathologic%20correlations.&amp;author=AM%20Mandard&amp;author=F%20Dalibard&amp;author=JC%20Mandard&amp;volume=73&amp;publication_year=1994&amp;pages=2680-6&amp;pmid=8194005&amp;doi=10.1002/1097-0142(19940601)73:11&amp;#x0003c;2680::aid-cncr2820731105&amp;#x0003e;3.0.co;2-c&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r14">
<span class="label">14.</span><cite>Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Nat Rev Cancer
2019;19:495-509. 10.1038/s41568-019-0179-8
</cite> [<a href="https://doi.org/10.1038/s41568-019-0179-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7043073/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31406302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Co-occurring%20genomic%20alterations%20in%20non-small-cell%20lung%20cancer%20biology%20and%20therapy.&amp;author=F%20Skoulidis&amp;author=JV%20Heymach&amp;volume=19&amp;publication_year=2019&amp;pages=495-509&amp;pmid=31406302&amp;doi=10.1038/s41568-019-0179-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r15">
<span class="label">15.</span><cite>Yan D.
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients.
Biomedicines
2023;11:2916. 10.3390/biomedicines11112916
</cite> [<a href="https://doi.org/10.3390/biomedicines11112916" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10669068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38001917/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Hope%20and%20Challenges:%20Immunotherapy%20in%20EGFR-Mutant%20NSCLC%20Patients.&amp;author=D.%20Yan&amp;volume=11&amp;publication_year=2023&amp;pages=2916&amp;pmid=38001917&amp;doi=10.3390/biomedicines11112916&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r16">
<span class="label">16.</span><cite>Peng S, Wang R, Zhang X, et al. 
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Mol Cancer
2019;18:165. 10.1186/s12943-019-1073-4
</cite> [<a href="https://doi.org/10.1186/s12943-019-1073-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6864970/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31747941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cancer&amp;title=EGFR-TKI%20resistance%20promotes%20immune%20escape%20in%20lung%20cancer%20via%20increased%20PD-L1%20expression.&amp;author=S%20Peng&amp;author=R%20Wang&amp;author=X%20Zhang&amp;volume=18&amp;publication_year=2019&amp;pages=165&amp;pmid=31747941&amp;doi=10.1186/s12943-019-1073-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r17">
<span class="label">17.</span><cite>Bao Y, Gu C, Xie H, et al. 
Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer.
Ann Transl Med
2021;9:493. 10.21037/atm-21-1134
</cite> [<a href="https://doi.org/10.21037/atm-21-1134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8039639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33850890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Transl%20Med&amp;title=Comprehensive%20study%20of%20neoadjuvant%20targeted%20therapy%20for%20resectable%20non-small%20cell%20lung%20cancer.&amp;author=Y%20Bao&amp;author=C%20Gu&amp;author=H%20Xie&amp;volume=9&amp;publication_year=2021&amp;pages=493&amp;pmid=33850890&amp;doi=10.21037/atm-21-1134&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r18">
<span class="label">18.</span><cite>Blakely CM, Urisman A, Gubens MA, et al. 
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
J Clin Oncol
2024;42:3105-14. 10.1200/JCO.24.00071
</cite> [<a href="https://doi.org/10.1200/JCO.24.00071" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11379363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39028931/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Neoadjuvant%20Osimertinib%20for%20the%20Treatment%20of%20Stage%20I-IIIA%20Epidermal%20Growth%20Factor%20Receptor-Mutated%20Non-Small%20Cell%20Lung%20Cancer:%20A%20Phase%20II%20Multicenter%20Study.&amp;author=CM%20Blakely&amp;author=A%20Urisman&amp;author=MA%20Gubens&amp;volume=42&amp;publication_year=2024&amp;pages=3105-14&amp;pmid=39028931&amp;doi=10.1200/JCO.24.00071&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r19">
<span class="label">19.</span><cite>Zhang Y, Fu F, Hu H, et al. 
Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
J Thorac Cardiovasc Surg
2021;161:434-442.e2. 10.1016/j.jtcvs.2020.02.131
</cite> [<a href="https://doi.org/10.1016/j.jtcvs.2020.02.131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32340810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Cardiovasc%20Surg&amp;title=Gefitinib%20as%20neoadjuvant%20therapy%20for%20resectable%20stage%20II-IIIA%20non-small%20cell%20lung%20cancer:%20A%20phase%20II%20study.&amp;author=Y%20Zhang&amp;author=F%20Fu&amp;author=H%20Hu&amp;volume=161&amp;publication_year=2021&amp;pages=434-442.e2&amp;pmid=32340810&amp;doi=10.1016/j.jtcvs.2020.02.131&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r20">
<span class="label">20.</span><cite>Zhong W, Yang X, Yan H, et al. 
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
J Hematol Oncol
2015;8:54. 10.1186/s13045-015-0151-3
</cite> [<a href="https://doi.org/10.1186/s13045-015-0151-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4455050/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25981169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Phase%20II%20study%20of%20biomarker-guided%20neoadjuvant%20treatment%20strategy%20for%20IIIA-N2%20non-small%20cell%20lung%20cancer%20based%20on%20epidermal%20growth%20factor%20receptor%20mutation%20status.&amp;author=W%20Zhong&amp;author=X%20Yang&amp;author=H%20Yan&amp;volume=8&amp;publication_year=2015&amp;pages=54&amp;pmid=25981169&amp;doi=10.1186/s13045-015-0151-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r21">
<span class="label">21.</span><cite>Zhong WZ, Yan HH, Chen KN, et al. 
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
Signal Transduct Target Ther
2023;8:76. 10.1038/s41392-022-01286-3
</cite> [<a href="https://doi.org/10.1038/s41392-022-01286-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9950485/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36823150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Signal%20Transduct%20Target%20Ther&amp;title=Erlotinib%20versus%20gemcitabine%20plus%20cisplatin%20as%20neoadjuvant%20treatment%20of%20stage%20IIIA-N2%20EGFR-mutant%20non-small-cell%20lung%20cancer:%20final%20overall%20survival%20analysis%20of%20the%20EMERGING-CTONG%201103%20randomised%20phase%20II%20trial.&amp;author=WZ%20Zhong&amp;author=HH%20Yan&amp;author=KN%20Chen&amp;volume=8&amp;publication_year=2023&amp;pages=76&amp;pmid=36823150&amp;doi=10.1038/s41392-022-01286-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r22">
<span class="label">22.</span><cite>Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. 
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
J Clin Oncol
2020;38:1505-17. 10.1200/JCO.19.03136
</cite> [<a href="https://doi.org/10.1200/JCO.19.03136" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32150489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Updated%20Analysis%20From%20KEYNOTE-189:%20Pembrolizumab%20or%20Placebo%20Plus%20Pemetrexed%20and%20Platinum%20for%20Previously%20Untreated%20Metastatic%20Nonsquamous%20Non-Small-Cell%20Lung%20Cancer.&amp;author=S%20Gadgeel&amp;author=D%20Rodr%C3%ADguez-Abreu&amp;author=G%20Speranza&amp;volume=38&amp;publication_year=2020&amp;pages=1505-17&amp;pmid=32150489&amp;doi=10.1200/JCO.19.03136&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r23">
<span class="label">23.</span><cite>Herbst RS, Baas P, Kim DW, et al. 
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
2016;387:1540-50. 10.1016/S0140-6736(15)01281-7
</cite> [<a href="https://doi.org/10.1016/S0140-6736(15)01281-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Pembrolizumab%20versus%20docetaxel%20for%20previously%20treated,%20PD-L1-positive,%20advanced%20non-small-cell%20lung%20cancer%20(KEYNOTE-010):%20a%20randomised%20controlled%20trial.&amp;author=RS%20Herbst&amp;author=P%20Baas&amp;author=DW%20Kim&amp;volume=387&amp;publication_year=2016&amp;pages=1540-50&amp;pmid=26712084&amp;doi=10.1016/S0140-6736(15)01281-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r24">
<span class="label">24.</span><cite>Garon EB, Rizvi NA, Hui R, et al. 
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
2015;372:2018-28. 10.1056/NEJMoa1501824
</cite> [<a href="https://doi.org/10.1056/NEJMoa1501824" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25891174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Pembrolizumab%20for%20the%20treatment%20of%20non-small-cell%20lung%20cancer.&amp;author=EB%20Garon&amp;author=NA%20Rizvi&amp;author=R%20Hui&amp;volume=372&amp;publication_year=2015&amp;pages=2018-28&amp;pmid=25891174&amp;doi=10.1056/NEJMoa1501824&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r25">
<span class="label">25.</span><cite>Lisberg A, Cummings A, Goldman JW, et al. 
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
J Thorac Oncol
2018;13:1138-45. 10.1016/j.jtho.2018.03.035
</cite> [<a href="https://doi.org/10.1016/j.jtho.2018.03.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6063769/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29874546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=A%20Phase%20II%20Study%20of%20Pembrolizumab%20in%20EGFR-Mutant,%20PD-L1+,%20Tyrosine%20Kinase%20Inhibitor%20Na%C3%AFve%20Patients%20With%20Advanced%20NSCLC.&amp;author=A%20Lisberg&amp;author=A%20Cummings&amp;author=JW%20Goldman&amp;volume=13&amp;publication_year=2018&amp;pages=1138-45&amp;pmid=29874546&amp;doi=10.1016/j.jtho.2018.03.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r26">
<span class="label">26.</span><cite>Zhang C, Sun YX, Yi DC, et al. 
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Cell Rep Med
2024;5:101615. 10.1016/j.xcrm.2024.101615
</cite> [<a href="https://doi.org/10.1016/j.xcrm.2024.101615" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11293361/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38897205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep%20Med&amp;title=Neoadjuvant%20sintilimab%20plus%20chemotherapy%20in%20EGFR-mutant%20NSCLC:%20Phase%202%20trial%20interim%20results%20(NEOTIDE/CTONG2104).&amp;author=C%20Zhang&amp;author=YX%20Sun&amp;author=DC%20Yi&amp;volume=5&amp;publication_year=2024&amp;pages=101615&amp;pmid=38897205&amp;doi=10.1016/j.xcrm.2024.101615&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r27">
<span class="label">27.</span><cite>Yang JC, Lee DH, Lee JS, et al. 
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor-Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
J Clin Oncol
2024;42:4029-39. 10.1200/JCO.23.02747
</cite> [<a href="https://doi.org/10.1200/JCO.23.02747" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11608596/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39173098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Phase%20III%20KEYNOTE-789%20Study%20of%20Pemetrexed%20and%20Platinum%20With%20or%20Without%20Pembrolizumab%20for%20Tyrosine%20Kinase%20Inhibitor-Resistant,%20EGFR-Mutant,%20Metastatic%20Nonsquamous%20Non-Small%20Cell%20Lung%20Cancer.&amp;author=JC%20Yang&amp;author=DH%20Lee&amp;author=JS%20Lee&amp;volume=42&amp;publication_year=2024&amp;pages=4029-39&amp;pmid=39173098&amp;doi=10.1200/JCO.23.02747&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r28">
<span class="label">28.</span><cite>Mok T, Nakagawa K, Park K, et al. 
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
J Clin Oncol
2024;42:1252-64. 10.1200/JCO.23.01017
</cite> [<a href="https://doi.org/10.1200/JCO.23.01017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11095864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38252907/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Nivolumab%20Plus%20Chemotherapy%20in%20Epidermal%20Growth%20Factor%20Receptor-Mutated%20Metastatic%20Non-Small-Cell%20Lung%20Cancer%20After%20Disease%20Progression%20on%20Epidermal%20Growth%20Factor%20Receptor%20Tyrosine%20Kinase%20Inhibitors:%20Final%20Results%20of%20CheckMate%20722.&amp;author=T%20Mok&amp;author=K%20Nakagawa&amp;author=K%20Park&amp;volume=42&amp;publication_year=2024&amp;pages=1252-64&amp;pmid=38252907&amp;doi=10.1200/JCO.23.01017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r29">
<span class="label">29.</span><cite>Zhang N, Zeng Y, Du W, et al. 
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Int J Oncol
2016;49:1360-8. 10.3892/ijo.2016.3632
</cite> [<a href="https://doi.org/10.3892/ijo.2016.3632" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27499357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Oncol&amp;title=The%20EGFR%20pathway%20is%20involved%20in%20the%20regulation%20of%20PD-L1%20expression%20via%20the%20IL-6/JAK/STAT3%20signaling%20pathway%20in%20EGFR-mutated%20non-small%20cell%20lung%20cancer.&amp;author=N%20Zhang&amp;author=Y%20Zeng&amp;author=W%20Du&amp;volume=49&amp;publication_year=2016&amp;pages=1360-8&amp;pmid=27499357&amp;doi=10.3892/ijo.2016.3632&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r30">
<span class="label">30.</span><cite>Chen N, Fang W, Zhan J, et al. 
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
J Thorac Oncol
2015;10:910-23. 10.1097/JTO.0000000000000500
</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000500" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25658629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Upregulation%20of%20PD-L1%20by%20EGFR%20Activation%20Mediates%20the%20Immune%20Escape%20in%20EGFR-Driven%20NSCLC:%20Implication%20for%20Optional%20Immune%20Targeted%20Therapy%20for%20NSCLC%20Patients%20with%20EGFR%20Mutation.&amp;author=N%20Chen&amp;author=W%20Fang&amp;author=J%20Zhan&amp;volume=10&amp;publication_year=2015&amp;pages=910-23&amp;pmid=25658629&amp;doi=10.1097/JTO.0000000000000500&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r31">
<span class="label">31.</span><cite>Khalaf K, Hana D, Chou JT, et al. 
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
Front Immunol
2021;12:656364. 10.3389/fimmu.2021.656364
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.656364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8190405/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34122412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Aspects%20of%20the%20Tumor%20Microenvironment%20Involved%20in%20Immune%20Resistance%20and%20Drug%20Resistance.&amp;author=K%20Khalaf&amp;author=D%20Hana&amp;author=JT%20Chou&amp;volume=12&amp;publication_year=2021&amp;pages=656364&amp;pmid=34122412&amp;doi=10.3389/fimmu.2021.656364&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r32">
<span class="label">32.</span><cite>Yang CY, Liao WY, Ho CC, et al. 
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Eur J Cancer
2020;124:110-22. 10.1016/j.ejca.2019.10.019
</cite> [<a href="https://doi.org/10.1016/j.ejca.2019.10.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31760310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Association%20between%20programmed%20death-ligand%201%20expression,%20immune%20microenvironments,%20and%20clinical%20outcomes%20in%20epidermal%20growth%20factor%20receptor%20mutant%20lung%20adenocarcinoma%20patients%20treated%20with%20tyrosine%20kinase%20inhibitors.&amp;author=CY%20Yang&amp;author=WY%20Liao&amp;author=CC%20Ho&amp;volume=124&amp;publication_year=2020&amp;pages=110-22&amp;pmid=31760310&amp;doi=10.1016/j.ejca.2019.10.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r33">
<span class="label">33.</span><cite>Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer.
EMBO Rep
2014;15:1243-53. 10.15252/embr.201439246
</cite> [<a href="https://doi.org/10.15252/embr.201439246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4264927/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25381661/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EMBO%20Rep&amp;title=The%20extracellular%20matrix%20modulates%20the%20hallmarks%20of%20cancer.&amp;author=MW%20Pickup&amp;author=JK%20Mouw&amp;author=VM%20Weaver&amp;volume=15&amp;publication_year=2014&amp;pages=1243-53&amp;pmid=25381661&amp;doi=10.15252/embr.201439246&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="r34">
<span class="label">34.</span><cite>Sun L, Xu G, Liao W, et al. 
Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis.
Oncotarget
2017;8:39658-72. 10.18632/oncotarget.17340
</cite> [<a href="https://doi.org/10.18632/oncotarget.17340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5503641/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28487498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Clinicopathologic%20and%20prognostic%20significance%20of%20regulatory%20T%20cells%20in%20patients%20with%20hepatocellular%20carcinoma:%20a%20meta-analysis.&amp;author=L%20Sun&amp;author=G%20Xu&amp;author=W%20Liao&amp;volume=8&amp;publication_year=2017&amp;pages=39658-72&amp;pmid=28487498&amp;doi=10.18632/oncotarget.17340&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><article class="sub-article" id="tlcr-14-03-1032-prf"><section class="pmc-layout__citation font-secondary font-xs"><div>Transl Lung Cancer Res.</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Peer Review File</h1></hgroup><ul class="d-buttons inline-list"><li><button class="d-button" aria-controls="clp_a.c" aria-expanded="false">Copyright and License information</button></li></ul>
<div class="d-panels font-secondary-light"><div id="clp_a.c" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div></div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<p>Available at <a href="https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/prf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-711/prf</a></p>
<figure class="fig xbox font-sm" id="d67e1845"><div class="media p"><div class="caption">
<a href="/articles/instance/12000952/bin/tlcr-14-03-1032-prf.pdf" data-ga-action="click_feat_suppl" class="usa-link">tlcr-14-03-1032-prf.pdf</a><sup> (118KB, pdf) </sup>
</div></div>
<div class="p text-right font-secondary"><a href="figure/d67e1845/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></article><article class="sub-article" id="_ad93_"><section class="pmc-layout__citation font-secondary font-xs"><div></div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Associated Data</h1></hgroup><ul class="d-buttons inline-list"></ul>
<div class="d-panels font-secondary-light"></div>
<div></div>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
</div></section><section class="body sub-article-body"><section id="_adsm93_" lang="en" class="supplementary-materials"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>The article’s supplementary files as</p></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p">
<div class="caption">
<a href="/articles/instance/12000952/bin/tlcr-14-03-1032-rc.pdf" data-ga-action="click_feat_suppl" class="usa-link">tlcr-14-03-1032-rc.pdf</a><sup> (156.9KB, pdf) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.21037/tlcr-24-711</div>
</div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12000952/bin/tlcr-14-03-1032-coif.pdf" data-ga-action="click_feat_suppl" class="usa-link">tlcr-14-03-1032-coif.pdf</a><sup> (650.9KB, pdf) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.21037/tlcr-24-711</div>
</div></section></section></section></article><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Translational Lung Cancer Research are provided here courtesy of <strong>AME Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.21037/tlcr-24-711"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/tlcr-14-03-1032.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.5 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12000952/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12000952/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12000952%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000952/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12000952/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12000952/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40248739/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12000952/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40248739/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12000952/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12000952/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Wh3vBTEINanHsRFcwvcUqpe2gvJoSuy63s34Pc0m88y0v0QkhGeMSaY2Vo36s7Ur">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
